Definitive Contract 75D30121C12880
Award Date 9/29/21
Potential Completion Date 3/28/26
Potential Value $5.2M
Federal Agency
Awardee
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Centers for Disease Control and Prevention (CDC) Pittsburgh division awarded a $10.67 million cost-reimbursable contract to King County's Public Health-Seattle & King County division on January 1, 2021, with a completion date of December 31, 2030. This definitive contract, awarded competitively with no set-aside designation, supports tuberculosis clinical trials and consortium services. The primary deliverables include participation in clinical research studies, adherence to study...
- The Centers for Disease Control and Prevention (CDC) awarded a $4,455,976 cost-no-fee definitive contract to The Regents of the University of California, San Francisco (UCSF) to develop, implement, and evaluate interventions to improve latent tuberculosis infection (LTBI) identification and treatment among high-risk non-U.S.-born populations in primary care settings. This contract, known as Tuberculosis Epidemiologic Studies Consortium III (TBESC3), has a period of performance from September 29,...
- This federal contract award to Kaiser Foundation Hospitals, a subsidiary of Kaiser Foundation Health Plan, Inc., supports the Centers for Disease Control and Prevention's (CDC) efforts to improve identification and treatment of latent tuberculosis infection (LTBI) among high-risk non-U.S.-born populations in primary care settings. The $5,223,415 definitive contract, awarded on September 29, 2021 without a set-aside, will fund the development, implementation, and evaluation of LTBI intervention...
- The Centers for Disease Control and Prevention (CDC) awarded a $4,679,587.20 Definitive Contract to the Denver Health and Hospital Authority (Denver Health) to develop, implement, and evaluate intervention studies to improve identification of latent tuberculosis infection (LTBI) and treatment-to-cure for high-risk non-U.S.-born populations in primary care settings. This contract, which does not have a set-aside designation, has a period of performance from September 29, 2021 through March 28,...
- The Centers for Disease Control and Prevention (CDC) awarded a definitive cost-no-fee contract valued at $3.78M to Denver Health and Hospital Authority for tuberculosis trials and consortium services. The contract, effective January 1, 2021, and extending through December 31, 2030, supports clinical research activities under the CDC's broader tuberculosis prevention and treatment initiatives. Denver Health will serve as a participating site in the Tuberculosis Trials Consortium, conducting...
- This federal contract, valued at $3,752,362.88, was awarded by the Centers for Disease Control and Prevention (CDC) to the University of North Texas Health Science Center at Fort Worth (UNTHSC) to conduct a comparative study on tuberculosis (TB) testing methods. The contract is part of the Tuberculosis Epidemiology Studies Consortium, an indefinite delivery contract, and does not have a set-aside designation. Under this task order, UNTHSC is evaluating the performance of the tuberculin skin test...
- This is a delivery order awarded by the Centers for Disease Control and Prevention (CDC) to the Hawaii Department of Health - Children With Special Health Needs - NBS Division, a state government entity, to conduct a comparison of tuberculosis skin tests (TST) versus interferon-gamma release assays (IGRA) in patients with latent tuberculosis infection (LTBI). The $3,733,229.06 cost-no-fee contract has an ultimate completion date of September 29, 2021 and is a delivery order under the...
- Research Triangle Institute (RTI) International was awarded a $707,813 time and materials contract by the Department of Health and Human Services Centers for Disease Control and Prevention to provide cost effectiveness analysis services for the Tuberculosis Epidemiologic Studies Consortium III (TBESC-III). The contract calls for RTI to design and implement cost effectiveness analyses of clinical interventions to improve performance across the latent tuberculosis infection care cascade. RTI...
- This is a $86,597,961.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Seattle Children's Hospital to support the Immune Mechanisms of Protection Against Mycobacterium Tuberculosis (IMPAC-TB) Center. The contract is not set aside for any specific business type. The IMPAC-TB Center aims to inform the rational design of an effective tuberculosis (TB) vaccine by identifying immune responses capable of controlling or eradicating Mycobacterium...
- This is a definitive cost-reimbursement contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to the Denver Health and Hospital Authority (Denver Health) for the Tuberculosis Trials Consortium (TBTC). The contract, which does not have a set-aside designation, has a potential value of $311,831.31 and a completion date of October 9, 2022. As a 555-bed academic health system and the region's only Level I trauma center, Denver Health...